Outcomes in patients ≥ 80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy
Autor: | Mairéad G McNamara, C Cipriano, R Hubner, A Lamarca, Hussain Raja, Xiaotian Wang, Alexandra R Lewis, A Rashed, Ward Re, Andrew M. Scott, Juan W. Valle, A Fitzpatrick |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Cancer Research medicine.medical_specialty Carcinoma Hepatocellular elderly oncology geriatric Comorbidity Kaplan-Meier Estimate Malignancy 03 medical and health sciences 0302 clinical medicine Older patients Internal medicine medicine cancer Humans In patient Retrospective Studies Aged 80 and over Hematology Manchester Cancer Research Centre business.industry Incidence (epidemiology) ResearchInstitutes_Networks_Beacons/mcrc Incidence Liver Neoplasms Cancer Age cohorts General Medicine medicine.disease Prognosis Survival Analysis Clinical trial Pancreatic Neoplasms Biliary Tract Neoplasms Treatment Outcome Oncology 030220 oncology & carcinogenesis Female hepatobiliary business |
Zdroj: | Lewis, A R, Cipriano, C, Wang, X, Ward, R, Fitzpatrick, A, Scott, A R M, Rashed, A, Raja, H, Lamarca, A, Hubner, R A, Valle, J & Mcnamara, M 2019, ' Outcomes in patients ≥80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy ', Medical Oncology . https://doi.org/10.1007/s12032-019-1310-0 |
ISSN: | 1559-131X |
DOI: | 10.1007/s12032-019-1310-0 |
Popis: | Introduction: Older patients are underrepresented in oncological clinical trials. The incidence of hepatopancreaticobiliary (HPB) malignancies is higher in older patients, but data on outcomes is lacking. Objectives: This study assessed patient outcomes in those 1) was not. Conclusions: Baseline factors were similar in both age cohorts, but more co-morbidities were present in older patients. Older patients were less likely to receive SACT, but when they did, they had an equivalent benefit in OS to younger patients. |
Databáze: | OpenAIRE |
Externí odkaz: |